https://scholars.lib.ntu.edu.tw/handle/123456789/145437
標題: | Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non-Small-Cell Lung Cancer | 作者: | Lee, Jih-Hsiang Lin, Yu-Lin Hsu, Wei-Hsun Chen, Hsuan-Yu Chang, Yeun-Chung Yu, Chong-Jen Shih, Jin-Yuan Lin, Chia-Chi Chen, Kuan-Yu Ho, Chao-Chi Laio, Wei-Yu Yang, Pan-Chyr Yang, James Chih-Hsin 楊泮池 |
關鍵字: | Non-small-cell lung cancer;BIM deletion polymorphism;Prognosis | 公開日期: | 2014 | 卷: | 9 | 期: | 9 | 起(迄)頁: | 1385-1392 | 來源出版物: | J. Thorac. Oncol. | 摘要: | Introduction: Germline Bcl-2-like protein 11 (BIM) deletion polymorphism in Asian is a poor predictive factor for treatment outcomes to tyrosine kinase inhibitors (TKIs) in malignancies. We explored the impact of BIM deletion polymorphism on treatment outcome of advanced non-small-cell lung cancer (NSCLC). ;Methods: We prospectively collected tissue samples, blood, and clinical data from two cohorts of advanced NSCLC patients. BIM deletion polymorphism was correlated with overall survival (OS) and progression-free survival (PFS) to epidermal growth factor receptor (EGFR) TKIs and chemotherapy treatment. ;Results: BIM deletion polymorphism was detected in blood of 16.2% (33 of 204) patients. The PFS to first-line EGFR-TKIs in 153 patients were 8.6 and 4.6 months for patients with wild-type BIM and BIM deletion polymorphism, respectively (p = 0.004). Among 120 patients who received chemotherapies, the PFS to chemotherapies were 5.6 and 3.5 months for patients with wild-type BIM and BIM deletion polymorphism, respectively (p = 0.050). The OS of all 204 patients was 24.8 and 16.8 months for patients with wild-type BIM and BIM deletion polymorphism, respectively (p = 0.005). Multivariate analyses suggested that BIM deletion polymorphism was an independent predictor for shorter PFS to EGFR-TKIs (hazard ratio [HR] 2.15, p = 0.002), PFS to chemotherapy (HR 2.40, p = 0.016), and OS (HR 1.65, p = 0.039). ;Conclusions: BIM deletion polymorphism predicts shorter PFS to EGFR-TKIs and OS in advanced NSCLC. |
URI: | http://ntur.lib.ntu.edu.tw//handle/246246/279657 |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。